BMRN Q1 2018 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$373M+22.9% YoY

Gross Profit

$291M78.0% margin

Operating Income

-$44M-11.9% margin

Net Income

-$44M-11.8% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$73M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.8B

Stockholders' Equity

$2.8B

Cash & Equivalents

$474M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$373M	$304M	+22.9%
Gross Profit	$291M	$254M	+14.7%
Operating Income	-$44M	-$20M	-119.6%
Net Income	-$44M	-$16M	-171.0%

Revenue Segments

Product Four

$117M32%

Product Three

$99M27%

Product Two

$75M20%

Product One

$66M18%

Product Six

$7M2%

Product Five

$5M1%

Geographic Segments

Latin America

$28M100%